Close Menu


Lower Response

Two studies indicated that the SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna have lower neutralizing antibody responses to the B.1.351 viral lineage, according to the Washington Post.

The researchers identified phenotypes of SARS-CoV-2-specific T cells as well as viral epitopes involved in T cell response that could aid future vaccine design.

According to the New York Times, President-elect Joe Biden is nominating Xavier Becerra to lead the Department of Health and Human Services.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.

Early data from Moderna suggests its candidate SARS-CoV-2 vaccine is highly effective, writes the Washington Post.

If It's Really Good

Late-stage vaccine trials could be stopped early if the data coming out of them is overwhelmingly positive, the Los Angeles Times reports.

The US National Institutes of Health is establishing the Centers for Research in Emerging Infectious Diseases to study pathogen spillover.

CNN reports the change in the US Centers for Disease Control and Prevention's coronavirus testing guidelines was in response to administration pressure.

A Rush on It?

The Financial Times reports the Trump Administration is exploring an Emergency Use Authorization for a coronavirus vaccine for October.

Phase III Begins

NPR reports Moderna has begun Phase III testing of its candidate SARS-CoV-2 vaccine.


Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.